Three-Drug attack on Tough-to-Treat lung cancer

This study is testing whether a three-drug combination can help control advanced lung cancer that has a specific genetic change called an EGFR exon 20 insertion. It will involve about 54 adults with this type of non-squamous non-small cell lung cancer who haven't had prior treatment for their advanced disease. Researchers want to see if adding the immunotherapy drug pembrolizumab and the anti-angiogenesis drug bevacizumab to standard chemotherapy is safe and effective at shrinking tumors and delaying cancer growth.